What were the key takeaways from Co-diagnostics’s earnings call?

Did Co-diagnostics beat or miss consensus estimates last quarter?

What factors drove the changes in Co-diagnostics's revenue and profit?

What does Co-diagnostics do and what are its main business segments?

What is Co-diagnostics's gross profit margin?

What guidance did Co-diagnostics's management provide for the next earnings period?

What is the market's earnings forecast for Co-diagnostics next quarter?

What is the revenue and EPS growth rate for Co-diagnostics year over year?

- **Strategic Momentum**: Advanced India expansion (CoSara SPAC exploration, $13B South Asia market), Saudi Arabia manufacturing, and TB clinical trials aligned with WHO guidelines.
- **Clinical Pipeline Progress**: Upper respiratory test nearing FDA submission; TB program targeting Q3 2026 India launch. Removed COVID-19 target but保留flexibility to reintroduce.
- **Financial Challenges**: 2025 net loss $46.9M due to $18.9M impairment charge; cash down 60% to $11.9M. Focus on disciplined spending and ATM capital access.
- **AI & IP Strength**: Expanded AI capabilities for predictive diagnostics; secured key patents in Japan and Australia.
- **Commercialization Timeline**: Target TB test launch in India Q3 2026; U.S. FDA submission for flu/RSV test pending analytical studies.


**【CEO Summary Section】**
- **Strategic Growth Pillars**: Focus on advancing clinical pipeline (TB, HPV, upper respiratory tests), expanding in India via CoSara (potential SPAC transaction), Saudi Arabia via CoMira, and AI-driven innovation.
- **India Expansion (CoSara)**: Received CDSCO manufacturing license for PCR Pro; expanded to South Asia ($13B addressable market). Planning TB clinical studies aligned with WHO guidelines using tongue swab sampling.
- **Saudi Arabia (CoMira)**: First domestic molecular diagnostics manufacturer; manufacturing facility nearing readiness for 18 MENA markets.
- **Clinical Pipeline**: Upper respiratory test (flu A/B, RSV) nearing FDA submission; TB and HPV programs advancing. Removed COVID-19 target due to low sample availability, but保留flexibility to add back.
- **AI Integration**: Co-Dx Primer AI platform enhances assay design, data analysis, and predictive insights for outbreak detection.
- **IP Expansion**: Secured international patents for PCR Pro technology in Australia and Japan.

**【CFO Financial Commentary】**
- **2025 Financials**: Total revenue $0.6M (down 85% YoY), product revenue $0.4M (down 50% YoY). Net loss $46.9M (up 24% YoY) due to $18.9M non-cash impairment charge. Adjusted EBITDA loss $28.0M (narrowed 17% YoY).
- **Expense Management**: Operating expenses $50.6M (up 17% YoY) driven by R&D and clinical trials. Excluding impairment, expenses down 14% YoY.
- **Liquidity**: $11.9M cash (down 60% YoY) from $29.7M. ATM facility provides capital flexibility.
- **2026 Outlook**: Continued losses expected as company advances clinical pipeline and commercialization.

**【Q&A Highlights】**
- **Clinical Trial Flexibility**: Removed COVID-19 target due to low samples; could add back with FDA consultation requiring ~30 positive samples.
- **South Asia Expansion**: Similar disease burden to India; CoSara leveraging existing infrastructure to expand into $13B market.
- **India Commercialization**: Target TB test launch Q3 2026; manufacturing and clinical trials underway. PCR Pro device shipping for local production.
- **U.S. FDA Study**: 1,200+ patient enrollment complete; analytical studies nearing submission.


Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript

- **Strategic Growth Initiatives**: SPAC transaction for CoSara, CoMira joint venture in Saudi Arabia, AI-driven diagnostics, and clinical trials for multiplex respiratory test.
- **Financial Resilience**: Q3 net loss improved 39% YoY to $5.9M, with $11.4M cash and cost-cutting measures.
- **Market Expansion**: Targeting $73.5B infectious disease diagnostics market, with focus on India and MENA via localized manufacturing and AI-enhanced testing.
- **Innovation Highlight**: PCR Pro device priced under $500, leveraging Co-Primer technology for cost-effective multiplex testing.

**【CEO Summary Section】**
- **Four Growth Pillars**: 
  1. **CoSara SPAC Transaction**: Engaged Maxim Group to explore a SPAC merger for the Indian joint venture, aiming to unlock value and provide growth capital for India operations.
  2. **CoMira Joint Venture**: Launched with Arabian Eagle to localize Co-Dx PCR technology in Saudi Arabia and 18 MENA countries, targeting regional healthcare innovation and regulatory compliance (SFDA).
  3. **AI Business Unit**: Launched Co-Dx Primer AI platform to enhance operational efficiency, automate test interpretation, and deliver predictive epidemiological insights.
  4. **Clinical Evaluations**: Initiated upper respiratory multiplex test (flu A/B, COVID-19, RSV) clinical trials, supported by NIH RADx Tech grant, with potential for U.S. and MENA market submissions.
- **Financial Strength**: Closed $10.8M in direct offerings, ending Q3 with $11.4M in cash, supporting near-term milestones and 2026 commercial launches.

**【CFO Financial Commentary】**
- **Revenue**: $0.1M (Q3 2025) vs. $0.6M (Q3 2024), with all revenue from product sales (vs. $0.4M grants last year).
- **Operating Expenses**: $7.1M (down 33% YoY), driven by cost optimization.
- **Net Loss**: $5.9M (Q3 2025) vs. $9.7M (Q3 2024), with adjusted EBITDA loss of $6.3M (improved 28% YoY).
- **Balance Sheet**: $11.4M in cash, with focus on operational efficiency and strategic financing.

**【Q&A Highlights】**
- **CoSara & CoMira Performance**: Both ventures exceed expectations; CoSara has a mature manufacturing footprint in India, while CoMira leverages Saudi Arabia's largest customer base for PCR tests.
- **SPAC & MTB/HPV Programs**: Potential licensing or distribution agreements for tuberculosis and HPV tests in India post-SPAC transaction.
- **Affordability of PCR Pro**: Price point under $500 at scale, enabled by simplified design (no need for complex thermal cyclers) and Co-Primer technology for multiplexing.
- **Middle East Relevance**: Co-Dx PCR Pro addresses upper respiratory infections (flu, COVID, RSV), aligning with Saudi Arabia's healthcare priorities under Vision 2030.

Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript

- **Clinical Milestones**: All four Co-DX PCR tests (COVID-19, respiratory panel, TB, HPV) to enter clinical trials by end-2025, with U.S. FDA submissions expected in 2026.
- **Market Focus**: U.S. COVID-19 test targeting mid-2026 launch; India/Africa TB/HPV tests prioritized for high-need regions.
- **Financial Position**: $13.4M cash reserves; cost-cutting efforts reduce operating expenses by 19% YoY.

**【CEO Summary Section】**
- **Co-DX PCR Platform Progress**: All four tests (COVID-19, 4-plex respiratory panel, TB, HPV) are set to begin clinical evaluations by end-2025. COVID-19 trial recruitment is imminent, followed by the respiratory panel, TB, and HPV.
- **Market Focus**: Prioritizes U.S. for COVID-19 and respiratory panel (targeting physician offices, SNFs, pharmacies); India and Africa for TB and HPV (30,000+ primary care centers in India).
- **Manufacturing**: Domestic facility in Utah and CoSara (India) for test kits and instruments; commercial launch expected mid-2026.
- **Data Feature**: Cloud-based analytics for real-time epidemiological insights, supported by Gates Foundation and NIH grants.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Revenue $0.2M (vs. $2.7M YoY), driven by product sales (prior year grants $2.5M). Operating expenses down 19% to $8.2M (vs. $10.1M YoY).
- **Financial Health**: Net loss $7.7M (-$0.23/share), EBITDA loss $7.2M. Cash reserves $13.4M; ATM and grant funding to support 2026 commercialization.

**【Q&A Key Highlights】**
- **Clinical Trial Cadence**: COVID-19 first, followed by respiratory panel, TB, HPV. FDA 510(k) submissions expected post-trial completion.
- **Commercial Timing**: Mid-2026 launch for U.S. COVID-19 test; India/Africa TB/HPV tests pending local regulatory approvals.
- **Market Strategy**: U.S. focus on point-of-care and home use; India targeting primary care centers with affordable PCR technology.

Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript

- **Platform Milestones**: Co-Dx PCR COVID-19 test design finalized; TB, respiratory, and HPV panels set for clinical trials in late 2025.
- **Market Focus**: India prioritized for TB and HPV launches, leveraging existing manufacturing infrastructure.
- **Financial Resilience**: Operating expenses down 18% YoY; $21.5M cash reserve supports regulatory efforts.
- **Pricing Strategy**: Devices target $300-500 range; test cups priced $15-20 in developed markets, lower in low-income regions.


**【CEO Summary Section】**
- **Platform Advancements**: The Co-Dx PCR platform is nearing regulatory submissions, with updated COVID-19 test design complete and verification testing successful. Clinical trials for TB, 4-plex respiratory, and 8-plex HPV panels are expected to begin in late 2025.
- **Test Pipeline Progress**: 
  - **TB Test**: Clinical evaluations in India and South Africa planned for H2 2025, leveraging existing infrastructure in India.
  - **COVID-19 Test**: FDA 510(k) submission pending collection of updated clinical data, with design enhancements for efficiency.
  - **4-plex Respiratory Panel**: Designed for simultaneous detection of flu A/B, COVID-19, and RSV, with FDA pre-submission completed.
  - **8-plex HPV Panel**: Targets eight high-risk HPV subtypes, with clinical trials set to begin in 2025.
- **Partnerships & Events**: Collaborated with Bill & Melinda Gates Foundation, SMART4TB, and NIH RADx Tech program. Hosted HPV awareness events in India and showcased platform at BioUtah.
- **Manufacturing Expansion**: India manufacturing facility nearing completion, including oligonucleotide synthesis capabilities.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q1 2025 revenue $0.1M (vs. $0.5M in Q1 2024), driven by product sales.
- **Cost Management**: Operating expenses decreased 18% YoY to $8.6M, with R&D expenses down 14% to $4.9M.
- **Financial Health**: Net loss narrowed to $7.5M (vs. $9.3M), cash reserves at $21.5M. Focused on operational efficiency and capital preservation.
- **Future Strategy**: Equity financing, grant funding, and cost optimization to support regulatory submissions and commercial launch.

**【Q&A Key Takeaways】**
- **COVID-19 Test Timeline**: Submission timing dependent on COVID prevalence; clinical trials expected to commence in 2025.
- **Global Launch Strategy**: HPV and TB tests prioritized for India due to high disease burden; pricing varies by geography ($15-20 per test cup in developed markets).
- **Margin Expectations**: Device margins similar to prior lab-based tests; test cup margins aligned with historical performance.


Co-Diagnostics (CODX)-8 May 25-2025 Q1 Earnings call transcript

- **Regulatory Momentum**: Resubmitting enhanced COVID-19 test with updated clinical data; TB and HPV tests advancing toward clinical trials in India and Africa.
- **Manufacturing Scale-Up**: New facilities in Utah and India support in-country production and regulatory compliance.
- **Financial Challenges**: FY2024 net loss of $37.6M driven by legal expenses, though cash reserves remain strong at $29.7M.
- **Strategic Flexibility**: Demonstrated ability to rapidly develop and adapt diagnostic tests (e.g., H5N1 avian flu test).

**【Management Opening Remarks】**
- Andrew Benson provided an overview of the call, emphasizing the company's focus on advancing its Co-Dx PCR platform and test pipeline. He highlighted the importance of regulatory submissions and manufacturing infrastructure development.

**【CEO Commentary】**
- **Regulatory Progress**: Withdrew the initial 510(k) submission for the COVID-19 test due to component stability concerns, planning to resubmit with updated clinical data. The new test design is complete and undergoing verification.
- **Test Pipeline Updates**: 
  - **COVID-19 Test**: Design updates incorporate recent platform enhancements for improved efficiency.
  - **TB Test**: Completed preliminary analytical studies; clinical evaluations in India and South Africa expected in H2 2025.
  - **Respiratory Multiplex Test**: FDA pre-submission completed; clinical evaluations to begin in H2 2025.
  - **HPV Multiplex Test**: Chemistry optimization complete; clinical study planning underway in India.
- **Manufacturing Expansion**: Inaugurated facilities in Utah (US) and India to support in-country production and regulatory compliance (e.g., Make in India initiative).
- **Partnerships**: Collaborating with Bill & Melinda Gates Foundation, NIH RADx Tech, and local health organizations to accelerate commercialization.

**【CFO Financial Commentary】**
- **Revenue**: FY2024 total revenue $3.9M (down from $6.8M FY2023), with $3.1M from grants and $0.8M from product sales.
- **Gross Profit**: Increased to $2.9M (from $2.6M FY2023).
- **Operating Expenses**: Decreased to $43.0M (from $45.3M FY2023), driven by reduced platform development costs.
- **Legal Expenses**: Surged to $7.0M (from $1.7M FY2023) due to securities litigation defense; one case dismissed in March 2025.
- **Net Loss**: $37.6M (vs. $35.3M FY2023), with adjusted EBITDA loss of $33.5M.
- **Liquidity**: $29.7M in cash as of Q4 2024, with plans to manage expenses and pursue equity financing in 2025.

**【Q&A Highlights】**
- **Avian Flu Test**: Company has developed an H5N1 test and is prepared to adapt it for human or avian use, depending on demand.
- **Regulatory Strategy**: Emphasized flexibility in test design to address emerging public health needs.


Actual																		-9.3	-7.5	-9.6	-10.8	-7.2	-6.9	-4.8
Forecast																		-6.3	-10.2	-9.9	-10.2	-8.1	-7.5	-5.7	-3.6
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-47.62%	+26.47%	+3.03%	-5.88%	+11.11%	+8.00%	+15.79%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	500.00K	2.66M	641.14K	149.32K	50.28K	162.91K	145.38K	--
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.10M	400.00K	375.00K	375.00K	200.00K	300.00K	300.00K	125.88K
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-83.87%	+564.21%	+70.97%	-60.18%	-74.86%	-45.70%	-51.54%	0.00%

CODX

CODX fundamentals

CODX Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

CODX

CODX fundamentals

CODX Q4 2025 Earnings Preview

Earnings Call

CODX Earnings Call Summary for Q4/20254:30 PM on Mar 31, 2026

CODX Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

CODX Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

CODX Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

CODX Earnings Call Summary for Q4/20244:30 PM on Mar 27, 2025

You can ask Aime